ArticlePloS one2016
Clinical Impact of MALDI-TOF MS Identification and Rapid Susceptibility Testing on Adequate Antimicrobial Treatment in Sepsis with Positive Blood Cultures.
Article in PloS one, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 54 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
54 citing papers in PubMed, 95 citations in OpenAlex.
- Trial
- Comparative analytical performance of Autof MS2600 and Biotyper Sirius for rapid MALDI-TOF MS identification of microorganisms from positive blood cultures.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2026Article
- Rapid Molecular Diagnostics for Bloodstream Infection in Patients with Chronic Kidney Disease.Diagnostics (Basel, Switzerland) · 2026Review
- Multidrug Resistance and Adaptive Response to Silver and Gold Nanoparticles in Methicillin-ResistantPathogens (Basel, Switzerland) · 2026Article
- Performance of direct-from-blood culture bottle rapid phenotypic antimicrobial susceptibility testing for Gram-negative bacteremia at a children's hospital.JAC-antimicrobial resistance · 2025Article
- Evaluation of direct microbial identification by MALDI-TOF MS and antimicrobial susceptibility testing for early diagnosis of blood stream infections.BMC microbiology · 2025Article
- Quality indicators and turnaround time for blood culture in pediatric patients: 1 year of monitoring in 19 Chinese hospitals.BMC pediatrics · 2025Article
- Evaluation of a new protocol for rapid identification ofJournal of clinical microbiology · 2025Article
- Rapid Characterization of Phospholipids from Biological Matrix Enabled by Indium Tin Oxide (ITO) Coated Slide Assisted Enrichment MALDI Mass Spectrometry.Analysis & sensing · 2024Article
- Empirical decision-making for antimicrobial therapy in critically ill patients.BJA education · 2023Review
- Early diagnosis of monomicrobialJournal of the Association of Medical Microbiology and Infectious Disease Canada = Journal officiel de l'Association pour la microbiologie medicale et l'infectiologie Canada · 2023Article
- Antimicrobial Multidrug Resistance: Clinical Implications for Infection Management in Critically Ill Patients.Microorganisms · 2023Review
- Short incubation of disc diffusion for Streptococcus pneumoniae and Haemophilus influenzae to reduce time to susceptibility report.The Journal of antimicrobial chemotherapy · 2023Article
- Impact of Rapid Molecular Diagnostic Technique on Time to Optimal Antimicrobial Therapy and Hospital Outcomes in Pediatric Cancer Patients with Sepsis.Asian Pacific journal of cancer prevention : APJCP · 2023Article
- Influence of Multiplex PCR in the Management of Antibiotic Treatment in Patients with Bacteremia.Antibiotics (Basel, Switzerland) · 2023Article
- The Role of Coagulase-Negative Staphylococci Biofilms on Late-Onset Sepsis: Current Challenges and Emerging Diagnostics and Therapies.Antibiotics (Basel, Switzerland) · 2023Review
- Diagnostic test accuracy of an automated device for the MALDI target preparation for microbial identification.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2023Article
- A Visualized Mortality Prediction Score Model in Hematological Malignancies Patients with Carbapenem-Resistant Organisms Bloodstream Infection.Infection and drug resistance · 2023Article
- Unresolved issues in the epidemiology and diagnosis of bacteremia: an opinion paper.Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia · 2022Review
- Rapid techniques for therapeutic optimization. Diagnostic stewardship.Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia · 2022Review
Corrections and comments
- Erratum issued
Authors and funding
7 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Shortening the turn-around time (TAT) of positive blood culture (BC) identification (ID) and susceptibility results is essential to optimize antimicrobial treatment in patients with sepsis. We aimed to evaluate the impact on antimicrobial prescription of a modified workflow of positive BCs providing ID and partial susceptibility results for Enterobacteriaceae (EB), Pseudomonas aeruginosa and Staphylococcus aureus on the day of BC positivity detection. This study was divided into a pre-intervention period (P0) with a standard BC workflow followed by 2 intervention periods (P1, P2) with an identical modified workflow. ID was performed with MALDI-TOF MS from blood, on early or on overnight subcultures. According to ID results, rapid phenotypic assays were realized to detect third generation cephalosporin resistant EB/P. aeruginosa or methicillin resistant S. aureus. Results were transmitted to the antimicrobial stewardship team for patient's treatment revision. Times to ID, to susceptibility results and to optimal antimicrobial treatment (OAT) were compared across the three study periods. Overall, 134, 112 and 154 positive BC episodes in P0, P1 and P2 respectively were included in the analysis. Mean time to ID (28.3 hours in P0) was reduced by 65.3% in P1 (10.2 hours) and 61.8% in P2 (10.8 hours). Mean time to complete susceptibility results was reduced by 27.5% in P1 and 27% in P2, with results obtained after 32.4 and 32.6 hours compared to 44.7 hours in P0. Rapid tests allowed partial susceptibility results to be obtained after a mean time of 11.8 hours in P1 and 11.7 hours in P2. Mean time to OAT was decreased to 21.6 hours in P1 and to 17.9 hours in P2 compared to 36.1 hours in P0. Reducing TAT of positive BC with MALDI-TOF MS ID and rapid susceptibility testing accelerated prescription of targeted antimicrobial treatment thereby potentially improving the patients' clinical outcome.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.